相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells
Hongwei Du et al.
CANCER CELL (2019)
Significance of MMP-9 and VEGF-C expression in North Indian women with breast cancer diagnosis
Krishna Latha Thammineni et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
Xuexiang Du et al.
CELL RESEARCH (2018)
FOXP3+Treg as a therapeutic target for promoting anti-tumor immunity
Theresa L. Whiteside
EXPERT OPINION ON THERAPEUTIC TARGETS (2018)
Cancer-FOXP3 directly activated CCL5 to recruit FOXP3+ Treg cells in pancreatic ductal adenocarcinoma
X. Wang et al.
ONCOGENE (2017)
Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer
Anthony S. Malamas et al.
ONCOTARGET (2017)
Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity
Yongkui Li et al.
ONCOIMMUNOLOGY (2016)
Biomarkers for adverse events associated with immune checkpoint inhibitors
Hampig Raphael Kourie et al.
BIOMARKERS IN MEDICINE (2016)
Targeting inhibition of Foxp3 by a CD28 2′-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy
Teresa Lozano et al.
BIOMATERIALS (2016)
Early dissemination seeds metastasis in breast cancer
Hedayatollah Hosseini et al.
NATURE (2016)
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
Anne Bertrand et al.
BMC MEDICINE (2015)
Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation
Teresa Lozano et al.
JOURNAL OF IMMUNOLOGY (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Expression and Clinical Significance of Matrix Metalloproteinase-9 in Lymphatic Invasiveness and Metastasis of Breast Cancer
Qiu-Wan Wu et al.
PLOS ONE (2014)
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
Luana Calabro et al.
LANCET ONCOLOGY (2013)
Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety
Lin Zhu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
Daisuke Sugiyama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Immunotherapy of cancer in 2012
John M. Kirkwood et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Targeting regulatory T cells
Christine Menetrier-Caux et al.
TARGETED ONCOLOGY (2012)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner
Xiang-Liang Yuan et al.
CLINICAL IMMUNOLOGY (2010)
Higher intratumoral infiltrated Foxp3+Treg numbers and Foxp3+/CD8+ratio are associated with adverse prognosis in resectable gastric cancer
Zhengbin Shen et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
A Peptide Inhibitor of FOXP3 Impairs Regulatory T Cell Activity and Improves Vaccine Efficacy in Mice
Noelia Casares et al.
JOURNAL OF IMMUNOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Immune Therapy for Cancer
Michael Dougan et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Overcoming Cancer Immune Tolerance and Escape
Guy T. Clifton et al.
CLINICAL CANCER RESEARCH (2009)
Nuclear Factor-κB Modulates Regulatory T Cell Development by Directly Regulating Expression of Foxp3 Transcription Factor
Meixiao Long et al.
IMMUNITY (2009)
Matrix Metalloproteinases As Novel Biomarkers and Potential Therapeutic Targets in Human Cancer
Roopali Roy et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Regulatory T cells and immune tolerance
Shimon Sakaguchi et al.
CELL (2008)
Cell penetrating peptides: Intracellular pathways and pharmaceutical perspectives
Leena N. Patel et al.
PHARMACEUTICAL RESEARCH (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Matrix metalloproteases: Underutilized targets for drug delivery
Deepali G. Vartak et al.
JOURNAL OF DRUG TARGETING (2007)
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse
Gaynor J. Bates et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative
F Ghiringhelli et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and-9
Toni Kline et al.
MOLECULAR PHARMACEUTICS (2004)
Control of regulatory T cell development by the transcription factor Foxp3
S Hori et al.
SCIENCE (2003)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
分享论文
